Review

bnt162b2 xbb.1.5-adapted mrna covid-19 vaccine (BioNTech)

Name: bnt162b2 xbb.1.5-adapted mrna covid-19 vaccine
Brand: BioNTech
Rating: 90 (1 reviews)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

BioNTech bnt162b2 xbb.1.5-adapted mrna covid-19 vaccine
Vaccine effectiveness against JN.1-related hospitalisation in SARI patients who received at least one dose of <t>BNT162b2</t> XBB vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season

Vaccine effectiveness against JN.1-related hospitalisation in SARI patients who received at least one dose of <t>BNT162b2</t> XBB vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season

Bnt162b2 Xbb.1.5 Adapted Mrna Covid 19 Vaccine, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bnt162b2 xbb.1.5-adapted mrna covid-19 vaccine/product/BioNTech
Average 90 stars, based on 1 article reviews

bnt162b2 xbb.1.5-adapted mrna covid-19 vaccine - by Bioz Stars, 2026-02

90/100 stars

Images

1) Product Images from "Durability of the BNT162b2 XBB.1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform"

Article Title: Durability of the BNT162b2 XBB.1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform

Journal: medRxiv

doi: 10.1101/2025.05.02.25326904

Vaccine effectiveness against JN.1-related hospitalisation in SARI patients who received at least one dose of BNT162b2 XBB vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season

Figure Legend Snippet: Vaccine effectiveness against JN.1-related hospitalisation in SARI patients who received at least one dose of BNT162b2 XBB vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season

Techniques Used:

Characteristics of study participants according to receipt of BNT162b2 XBB vaccine and SARS-CoV-2

Figure Legend Snippet:

Techniques Used:

Spline-based vaccine effectiveness by time since dose against JN.1-related hospitalisation among SARI patients who received at least one dose of BNT162b2 XBB vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season.

Figure Legend Snippet: Spline-based vaccine effectiveness by time since dose against JN.1-related hospitalisation among SARI patients who received at least one dose of BNT162b2 XBB vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season.

Techniques Used:

Similar Products

monovalent omicron xbb.1.5-adapted bnt162b2 covid-19 vaccine (Pfizer Inc)

Pfizer Inc monovalent omicron xbb.1.5-adapted bnt162b2 covid-19 vaccine
Monovalent Omicron Xbb.1.5 Adapted Bnt162b2 Covid 19 Vaccine, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/monovalent omicron xbb.1.5-adapted bnt162b2 covid-19 vaccine/product/Pfizer Inc
Average 90 stars, based on 1 article reviews

monovalent omicron xbb.1.5-adapted bnt162b2 covid-19 vaccine - by Bioz Stars, 2026-02

90/100 stars

Buy from Supplier

bnt162b2 xbb.1.5-adapted mrna covid-19 vaccine (BioNTech)

BioNTech bnt162b2 xbb.1.5-adapted mrna covid-19 vaccine

bnt162b2 xbb.1.5-adapted mrna covid-19 vaccine - by Bioz Stars, 2026-02

90/100 stars

Buy from Supplier

xbb.1.5 mrna vaccine bnt162b2 (BioNTech)

BioNTech xbb.1.5 mrna vaccine bnt162b2

Xbb.1.5 Mrna Vaccine Bnt162b2, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/xbb.1.5 mrna vaccine bnt162b2/product/BioNTech
Average 90 stars, based on 1 article reviews

xbb.1.5 mrna vaccine bnt162b2 - by Bioz Stars, 2026-02

90/100 stars

Buy from Supplier

bnt162b2 xbb.1.5 vaccine (BioNTech)

BioNTech bnt162b2 xbb.1.5 vaccine

Bnt162b2 Xbb.1.5 Vaccine, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bnt162b2 xbb.1.5 vaccine/product/BioNTech
Average 90 stars, based on 1 article reviews

bnt162b2 xbb.1.5 vaccine - by Bioz Stars, 2026-02

90/100 stars

Buy from Supplier

updated bnt162b2 omicron xbb.1.5 vaccine (BioNTech)

BioNTech updated bnt162b2 omicron xbb.1.5 vaccine

A – F Neutralization assessment for pseudo-typed particles with plasma post <t>BNT162b2</t> XBB.1.5 vaccination. Each mutant shown contains a single mutation reverting the amino acid mutation in BA.2.86 to the corresponding amino acid within BA.2. Particles pseudo-typed with the indicated S proteins were pre-incubated for one hour at 37 °C with plasma dilutions from double boostered health care workers. Pseudo-virus neutralization titer 50 (PVNT50) was calculated using the least squares fit using a variable slope, using a four-parameter nonlinear regression model. The lower limit of confidence (LLOC) was set at a PVNT50 of 50. Non responders are defined as individuals below this 60 (dashed line). All PVNT50 below 10 are set at 10 for visualization purposes. The assay was performed in technical duplicates and with negative controls to assess the virus input of each used pseudo-virus in the absence of plasma antibodies. Statistical significance was assessed by Friedman two sided nonparametric paired test (ns, p > 0.05; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001). Source data are provided as a Source Data file.

Updated Bnt162b2 Omicron Xbb.1.5 Vaccine, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/updated bnt162b2 omicron xbb.1.5 vaccine/product/BioNTech
Average 90 stars, based on 1 article reviews

updated bnt162b2 omicron xbb.1.5 vaccine - by Bioz Stars, 2026-02

90/100 stars

Buy from Supplier

bnt162b2 xbb.1.5-adapted mrna vaccine (BioNTech)

BioNTech bnt162b2 xbb.1.5-adapted mrna vaccine

Characteristics of study participants according to receipt of <t> BNT162b2 </t> XBB.1.5-adapted vaccine and SARS-CoV-2 case classification.

Bnt162b2 Xbb.1.5 Adapted Mrna Vaccine, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bnt162b2 xbb.1.5-adapted mrna vaccine/product/BioNTech
Average 90 stars, based on 1 article reviews

bnt162b2 xbb.1.5-adapted mrna vaccine - by Bioz Stars, 2026-02

90/100 stars

Buy from Supplier

bnt162b2 vaccine encoding the viral spike protein of sars-cov-2 omicron xbb.1.5 (comirnaty omicron xbb.1.5 (BioNTech)

BioNTech bnt162b2 vaccine encoding the viral spike protein of sars-cov-2 omicron xbb.1.5 (comirnaty omicron xbb.1.5

Bnt162b2 Vaccine Encoding The Viral Spike Protein Of Sars Cov 2 Omicron Xbb.1.5 (Comirnaty Omicron Xbb.1.5, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bnt162b2 vaccine encoding the viral spike protein of sars-cov-2 omicron xbb.1.5 (comirnaty omicron xbb.1.5/product/BioNTech
Average 90 stars, based on 1 article reviews

bnt162b2 vaccine encoding the viral spike protein of sars-cov-2 omicron xbb.1.5 (comirnaty omicron xbb.1.5 - by Bioz Stars, 2026-02

90/100 stars

Buy from Supplier

monovalent bnt162b2 vaccine encoding the viral spike protein of sars-cov-2 omicron xbb.1.5 (BioNTech)

BioNTech monovalent bnt162b2 vaccine encoding the viral spike protein of sars-cov-2 omicron xbb.1.5

Monovalent Bnt162b2 Vaccine Encoding The Viral Spike Protein Of Sars Cov 2 Omicron Xbb.1.5, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/monovalent bnt162b2 vaccine encoding the viral spike protein of sars-cov-2 omicron xbb.1.5/product/BioNTech
Average 90 stars, based on 1 article reviews

monovalent bnt162b2 vaccine encoding the viral spike protein of sars-cov-2 omicron xbb.1.5 - by Bioz Stars, 2026-02

90/100 stars

Buy from Supplier

vaccine bnt162b2 xbb.1.5 (BioNTech)

BioNTech vaccine bnt162b2 xbb.1.5

Vaccine Bnt162b2 Xbb.1.5, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vaccine bnt162b2 xbb.1.5/product/BioNTech
Average 90 stars, based on 1 article reviews

vaccine bnt162b2 xbb.1.5 - by Bioz Stars, 2026-02

90/100 stars

Buy from Supplier

Image Search Results

Journal: medRxiv

doi: 10.1101/2025.05.02.25326904

Figure Lengend Snippet: Vaccine effectiveness against JN.1-related hospitalisation in SARI patients who received at least one dose of BNT162b2 XBB vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season

Article Snippet: Since its authorisation by the European Medicines Agency (EMA) on 30 August 2023 [ ], numerous real-world studies have reported on the vaccine effectiveness (VE) of the BNT162b2 XBB.1.5-adapted mRNA COVID-19 vaccine (Pfizer/BioNTech 2023–2024 formulation, hereafter referred to as the BNT162b2 XBB vaccine) during the 2023–2024 season [ – ].

Techniques:

Journal: medRxiv

doi: 10.1101/2025.05.02.25326904

Figure Lengend Snippet:

Techniques:

Journal: medRxiv

doi: 10.1101/2025.05.02.25326904

Figure Lengend Snippet: Spline-based vaccine effectiveness by time since dose against JN.1-related hospitalisation among SARI patients who received at least one dose of BNT162b2 XBB vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season.

Techniques:

Journal: medRxiv

doi: 10.1101/2025.05.02.25326904

Techniques:

Journal: medRxiv

doi: 10.1101/2025.05.02.25326904

Techniques:

A – F Neutralization assessment for pseudo-typed particles with plasma post BNT162b2 XBB.1.5 vaccination. Each mutant shown contains a single mutation reverting the amino acid mutation in BA.2.86 to the corresponding amino acid within BA.2. Particles pseudo-typed with the indicated S proteins were pre-incubated for one hour at 37 °C with plasma dilutions from double boostered health care workers. Pseudo-virus neutralization titer 50 (PVNT50) was calculated using the least squares fit using a variable slope, using a four-parameter nonlinear regression model. The lower limit of confidence (LLOC) was set at a PVNT50 of 50. Non responders are defined as individuals below this 60 (dashed line). All PVNT50 below 10 are set at 10 for visualization purposes. The assay was performed in technical duplicates and with negative controls to assess the virus input of each used pseudo-virus in the absence of plasma antibodies. Statistical significance was assessed by Friedman two sided nonparametric paired test (ns, p > 0.05; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001). Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Reverse mutational scanning of SARS-CoV-2 spike BA.2.86 identifies epitopes contributing to immune escape from polyclonal sera

doi: 10.1038/s41467-025-55871-5

Figure Lengend Snippet: A – F Neutralization assessment for pseudo-typed particles with plasma post BNT162b2 XBB.1.5 vaccination. Each mutant shown contains a single mutation reverting the amino acid mutation in BA.2.86 to the corresponding amino acid within BA.2. Particles pseudo-typed with the indicated S proteins were pre-incubated for one hour at 37 °C with plasma dilutions from double boostered health care workers. Pseudo-virus neutralization titer 50 (PVNT50) was calculated using the least squares fit using a variable slope, using a four-parameter nonlinear regression model. The lower limit of confidence (LLOC) was set at a PVNT50 of 50. Non responders are defined as individuals below this 60 (dashed line). All PVNT50 below 10 are set at 10 for visualization purposes. The assay was performed in technical duplicates and with negative controls to assess the virus input of each used pseudo-virus in the absence of plasma antibodies. Statistical significance was assessed by Friedman two sided nonparametric paired test (ns, p > 0.05; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001). Source data are provided as a Source Data file.

Article Snippet: All participants donated blood directly prior to vaccination with 30 μg of the updated BNT162b2 Omicron XBB.1.5 vaccine (Raxtozinameran, BioNTech, Mainz, Germany) in September 2023 and were followed-up for another blood collection 15–16 days post vaccination .

Techniques: Neutralization, Clinical Proteomics, Mutagenesis, Incubation, Virus

Characteristics of study participants according to receipt of BNT162b2 XBB.1.5-adapted vaccine and SARS-CoV-2 case classification.

Journal: eClinicalMedicine

Article Title: Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platform

doi: 10.1016/j.eclinm.2024.102995

Figure Lengend Snippet: Characteristics of study participants according to receipt of BNT162b2 XBB.1.5-adapted vaccine and SARS-CoV-2 case classification.

Article Snippet: On 31 August 2023, the European Medicines Agency (EMA) authorized BNT162b2 XBB.1.5-adapted mRNA vaccine (Pfizer/BioNTech Manufacturing GmbH 2023–2024 formulation; hereafter referred to as BNT162b2 XBB vaccine) for the prevention of coronavirus disease 2019 (COVID-19) in individuals 6 months of age and older for the 2023–2024 autumn/winter season.

Techniques: Infection

Vaccine effectiveness 1 against COVID-19 hospitalization in SARI patients who received at least one dose of BNT162b2 XBB.1.5-adapted vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season. 1 Vaccine effectiveness estimates are adjusted for date of symptom onset, age, sex, and number of chronic conditions. 2 ‘Never vaccinated’ subjects were excluded when calculating the median (IQR) of time since last vaccine dose in the unexposed group (patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season). 3 The categories “Cancer” and “Immunodeficiency” among chronic conditions are counted as separate types of chronic conditions in all adjusted VE estimates. Here, the VE estimate among participants having “Immunodeficiency or cancer” is provided as a composite. 4 The categories “0” and “1” among the number of chronic conditions are counted as separate categories of number of chronic conditions in all adjusted VE estimates. Here, the VE estimate among participants having “0–1”chronic conditions is provided as a composite.

Journal: eClinicalMedicine

doi: 10.1016/j.eclinm.2024.102995

Figure Lengend Snippet: Vaccine effectiveness 1 against COVID-19 hospitalization in SARI patients who received at least one dose of BNT162b2 XBB.1.5-adapted vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season. 1 Vaccine effectiveness estimates are adjusted for date of symptom onset, age, sex, and number of chronic conditions. 2 ‘Never vaccinated’ subjects were excluded when calculating the median (IQR) of time since last vaccine dose in the unexposed group (patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season). 3 The categories “Cancer” and “Immunodeficiency” among chronic conditions are counted as separate types of chronic conditions in all adjusted VE estimates. Here, the VE estimate among participants having “Immunodeficiency or cancer” is provided as a composite. 4 The categories “0” and “1” among the number of chronic conditions are counted as separate categories of number of chronic conditions in all adjusted VE estimates. Here, the VE estimate among participants having “0–1”chronic conditions is provided as a composite.

Techniques:

Vaccine effectiveness 1 against COVID-19 hospitalization in SARI patients who received at least one dose of BNT162b2 XBB.1.5-adapted vaccine using various prior vaccination categories as reference groups. 1 Vaccine effectiveness estimates are adjusted for date of symptom onset, age, sex, and number of chronic conditions. 2 ‘Never vaccinated’ subjects were excluded when calculating the median (IQR) of time since last vaccine dose among patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season. 3 Stratifications of comparison groups were assessed on matched data per exposure of interest and numbers will therefore not add up to the numbers provided in <xref ref-type=

Table 1 . Patient characteristics of these subsets are shown in Supplementary Table S3 . " width="100%" height="100%">

Journal: eClinicalMedicine

doi: 10.1016/j.eclinm.2024.102995

Figure Lengend Snippet: Vaccine effectiveness 1 against COVID-19 hospitalization in SARI patients who received at least one dose of BNT162b2 XBB.1.5-adapted vaccine using various prior vaccination categories as reference groups. 1 Vaccine effectiveness estimates are adjusted for date of symptom onset, age, sex, and number of chronic conditions. 2 ‘Never vaccinated’ subjects were excluded when calculating the median (IQR) of time since last vaccine dose among patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season. 3 Stratifications of comparison groups were assessed on matched data per exposure of interest and numbers will therefore not add up to the numbers provided in Table 1 . Patient characteristics of these subsets are shown in Supplementary Table S3 .

Techniques: Comparison